

Mouse IgG-F(ab')₂ Fragment Cross-Adsorbed Antibody

F(ab')₂ Goat Polyclonal Conjugate Biotin

Antigen Affinity Purified

Catalog No. A90-241B

Lot No. A90-241B-8

APPLICATIONS	WB, IHC, ICC, ELISA
SPECIES REACTIVITY	Mouse. Minimum reactivity to human and rat
AMOUNT	1 ml
CONCENTRATION	0.5 mg/ml
STORAGE/SHELF LIFE	2 – 8°C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Phosphate Buffered Saline (PBS) containing 0.2% BSA and 0.09% Sodium Azide
ISOTYPE	IgG
ORIGIN	USA
PRODUCTION PROCEDURES	Antiserum was solid phase adsorbed to ensure class specificity. Antiserum was cross adsorbed using human and rat immunosorbents to remove cross reactive antibodies. The antibody to Mouse IgG-F(ab') ₂ Fragment was isolated by affinity chromatography using antigen coupled to agarose beads. F(ab') ₂ fragments were generated using a pepsin digestion. Fc fragments and whole IgG molecules have been removed. Fragments were conjugated to biotin.

Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.

By immunoelectrophoresis and ELISA this antibody reacts specifically with Fab fragment of mouse IgG and with light chains common to other mouse immunoglobulins. No antibody was detected against non-immunoglobulin serum proteins. This antibody may cross react with Fab fragments from other species.

APPLICATIONS Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.

Western Blot 1:10,000 – 1:200,000

Immunohistochemistry 1:250 – 1:2,500

Immunocytochemistry 1:100 – 1:500

ELISA 1:10,000 – 1:200,000

APPLICATION NOTES Not all listed applications have been specifically tested by our laboratory.

ADDITIONAL INFO <https://www.fortislifecom.com/p/A90-241B>

Use the link above to view SDS, a current list of citations, and other product specific information.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.
Michael Spencer, PhD Date: August 31, 2022